

# **Exhibit C**

UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK

BIONPHARMA INC.,  
Plaintiff,

v.

Case No. 1:21-CV-10656-JGK

CORERX, INC.,  
Defendant.

DECLARATION OF JEFF EDWARDS

I, Jeff Edwards, state the following under penalty of perjury:

1. I am a member of the board of directors of CoreRx, Inc. ("CoreRx"). I joined the CoreRx Board subsequent to an acquisition of the majority of the stock of CoreRx by a fund affiliated with NovaQuest Capital Management in January 2021.
2. I am a member of the board of directors of Azurity Pharmaceuticals, Inc. ("Azurity").
3. I have not been, and am not currently, involved in the daily management of CoreRx or Azurity. I did not make any decision about or provide any recommendation related to whether CoreRx should or should not (a) manufacture enalapril maleate oral liquid solution for, (b) sell enalapril maleate oral liquid solution to, or (c) stop manufacturing and selling enalapril maleate oral liquid solution for and to Bionpharma Inc. ("Bionpharma").
4. I had no advance knowledge that Azurity was planning to file any lawsuit against CoreRx. I did not learn about the lawsuit that I am told was filed by Azurity against CoreRx in October 2021 before it was filed. I did not learn about the lawsuit that I am told was filed by Azurity against CoreRx in April 2022 before it was filed.
5. After Azurity filed its lawsuit against CoreRx in October 2021, CoreRx's CEO,

Ajay Damani, asked me what he should do in response to the lawsuit. I informed Mr. Damani that because I was a member of the boards of both CoreRx and Azurity, I could not be involved in any way with the lawsuit. I recommended that Mr. Damani proceed as CEO in the manner that he thought would be in the best interest of CoreRx.

6. I did not have anything to do with CoreRx's decision to enter the November 24, 2021 Settlement Agreement between CoreRx and Azurity and did not have anything to do with determining the terms of the November 24, 2021 Settlement Agreement between CoreRx and Azurity. I did not discuss with anyone from CoreRx whether CoreRx should or should not settle with Azurity or the terms of any potential settlement. I did not know CoreRx and Azurity were going to enter a settlement agreement with each other until after they entered the November 24, 2021 Settlement Agreement.

7. In order to perform my duties as a board member of CoreRx, CoreRx's management, including Ajay Damani, provides me with information regarding the company. From the time when Mr. Damani was named as CEO of CoreRx until today, I do not believe I have any knowledge regarding CoreRx that Mr. Damani does not also possess.


8. I am one of five partners at QHP Capital ("QHP"), formerly part of NovaQuest Capital Management. I am one of the people in charge of transaction origination and execution, investment policy, and investor relations for QHP. I sit on the Private Equity Investment Committee for QHP. It would be burdensome both for me personally and for QHP for me to

prepare for and attend a deposition in this action.

9. I reside in and my office is in North Carolina.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on January 27, 2023.



Jeff Edwards